S&P Futures
5,901.25 -4.75 (-0.08%) Dow Futures
43,533.00 +15.00 (+0.03%) Nasdaq Futures
20,439.75 -43.75 (-0.21%) Russell 2000 Futures
2,295.20 +4.00 (+0.17%) Crude Oil
70.14 +0.92 (+1.33%) Gold
2,749.70 +19.70 (+0.72%)
Mind Medicine (MindMed) Inc. (MNMD)
After hours:
- TipRanks
Mind Medicine assumed with an Outperform at Leerink
Leerink assumed coverage of Mind Medicine with an Outperform rating and $20 price target The firm likes the emerging psychedelics space with increasing investment in clinical development across multiple psychiatric indications, clear FDA guidance, and more established commercial infrastructure following the launch of J&J’s Spravato. The firm also believes MM120 has a good chance of working based on published data. Published first on TheFly – the ultimate source for real-time, market-moving break
- Business Wire
MindMed Announces New Employee Inducement Grants
NEW YORK, September 09, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 70,000 common shares of the Company (the "Options"), with an effective grant date of September 9, 2024. The Options have an exercise price
